$19.78
+1.20 (+6.46%)
Open$18.93
Previous Close$18.58
Day High$19.88
Day Low$18.72
52W High$44.60
52W Low$8.91
Volume—
Avg Volume733.1K
Market Cap1.25B
P/E Ratio—
EPS$-8.45
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+49.2% upside
Current
$19.78
$19.78
Target
$29.51
$29.51
$22.12
$29.51 avg
$35.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 14.10M | 140.52M | 130.81M |
| Net Income | -532,610,166 | -116,113 | -126,311 |
| Profit Margin | -3,777.4% | -0.1% | -0.1% |
| EBITDA | -540,033,458 | -178,287 | -168,053 |
| Free Cash Flow | — | -139,366 | -118,293 |
| Rev Growth | — | -3.7% | +16.0% |
| Debt/Equity | 0.32 | 0.89 | 0.92 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |